权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunotherapy for acute lung injury secondary to influenza

流感继发急性肺损伤的免疫治疗

基本信息

批准号：
10133140
负责人：
PAUL R KNIGHT III
金额：
$ 43.68万
依托单位：
STATE UNIVERSITY OF NEW YORK AT BUFFALO
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10133140
关键词：
Acute Lung Injury Address Adverse effects Antiviral Agents Antiviral resistance Avian Influenza Bacterial Pneumonia Birds Cardiac Cations Cause of Death Cell Line Cells Cessation of life Chitosan Clinical Communicable Diseases Complex Coupled Development Disease Disease Outbreaks Drug Interactions Drug Kinetics Drug resistance Ebola Ebola virus Electrostatics Engineering Epidemic Epithelial Cells Etiology Formulation Foundations Genes Genetic Drift Hospitalization Human Immune Immune response Immune system Immunotherapy Impairment In Vitro Incidence Infection Infiltration Inflammatory Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza A Virus, H5N1 Subtype Influenza A virus Influenza B Virus Inhalation Inhalation Drug Administration Injury Innate Immune Response Interferon Type I Interferons Investigational Drugs Investigational New Drug Application Ligands Lung Mediating Morbidity - disease rate Mus Nanotechnology Natural Immunity Neuraminidase inhibitor Nonstructural Protein Nucleic Acids Oseltamivir Pathogenesis Pathogenicity Patients Pharmaceutical Preparations Phase I Clinical Trials Polymerase Population Preventive treatment Process Production RNA RNA Binding RNA Interference Resistance development Respiratory System Risk Secondary to Severities Standardization Symptoms Therapeutic Time Translations Treatment Efficacy Vaccines Viral Viral Pneumonia Virulence Virulence Factors Virulent Virus Work Zika Virus adaptive immune response airway epithelium antiviral immunity biomaterial compatibility comorbidity cytokine cytokine release syndrome design drug resistant influenza experimental study feasibility testing gene product improved in vivo influenza virus strain influenzavirus inhibitor/antagonist lung injury mortality nanoparticle novel novel strategies pandemic disease product development prophylactic resistant strain respiratory response seasonal influenza sensor swine flu transmission process treatment strategy tripolyphosphate viral resistance virology

项目摘要

PROJECT SUMMARY/ABSTRACT The emergence of drug-resistant strains of human influenza A (IAV) and B viruses, as well as avian H5N1 virus with pandemic potential, to the only approved antiviral agents underscores the importance of developing novel antiviral strategies. We have engineered electrostatic complexes between cationic nanoparticles (i.e., chitosan) and anionic RNA that target airway epithelial cells in vivo during an IAV infection. These nanoplexes induce antiviral bioactivity directed against IAV in vivo with little or no untoward cellular or pulmonary responses. The nanoplex constructs stimulate early type I interferon (IFN) cellular responses through 5’- triphosphate (PPP)-RNA binding of the intracellular sensor, RIG-I. Additionally, the 5’PPP-NS1shRNA nanoplex formulation suppresses the translation of the IAV virulence factor, NS1, which inhibits RIG-I and host cell RNA maturation. The lung is well suited for an antiviral nanoplex strategy since it provides a portal for inhalation administration of bioactive nanoplexes. We have demonstrated that this strategy inhibits in vivo IAV replication therapeutically and avoids the “IFN paradox”, specifically, decreasing IAV lung injury, and IAV impairment of bacterial clearance from the lung. The focus of the current proposal is to optimize the therapeutic action of the 5’PPP-NS1shRNA nanoplex formulation in vitro and then in vivo. Additionally, we propose to carry out experiments recommended by the FDA article entitled “Antiviral Product Development: Conducting and Submitting Virological Studies to the Agency.” This includes in vitro and in vivo experiments to assess therapeutic efficacy (antiviral activity), pharmacokinetics, drug-drug interactions, and development of viral resistance. Additionally, because the 5’PPP-NS1shRNA nanoplex modulates the immune response, the FDA recommends examining possible unintended adverse effects resulting from actions on the immune system. Thus, we will also identify the specific immune system components that are altered, as well as assess the immune-mediated complications of an IAV infection including increased severity of the respiratory tract injury, and the risk of IAV-associated secondary bacterial pneumonia, a major cause of death in influenza cases. Specifically, we will examine the ability of 5’PPP-NS1shRNA nanoplexes to stimulate innate antiviral immunity, thereby changing infiltration of inflammatory cells, inflammatory cytokine milieu, adaptive immune responses, as well as decrease respiratory injury and IAV-associated impairment of bacterial clearance. In addition to assessing the clearance of IAV from the respiratory tract, we predict that the nanoplex construct will reduce the morbidity and severity of symptoms of influenza from drug resistant seasonal and pandemic strains, the highly pathogenic H1N1 swine-origin IAV virus (S-OIV) and H5N1 “bird flu”. These nano-technological approaches can also potentially treat other infectious (i.e., Ebola) or non-infectious lung injuries. Our proposal is designed to produce a novel antiviral nanoplex formulation for Phase 1 clinical trials as an Investigational New Drug.

项目总结/文摘